Diabetes in the older person Terry Aspray Tuesday pm.

Slides:



Advertisements
Similar presentations
Insulin Therapy in Type 2 Diabetes: Current and Future Directions
Advertisements

NEW ORAL AGENTS IN DIABETES MANAGEMENT
A Resource for Glycaemic management in Type 2 DM Hypoglycaemia is dangerous: Beware in Elderly/RF/CVS risk Sulphonureas need education to avoid risk Do.
A Resource for Glycaemic management in Diabetes key messages Hypoglycaemia is dangerous: Beware in elderly/RF/CVS risk Sulphonylureas need education to.
Emma Harris Medicines Management Pharmacist West Suffolk Clinical Commissioning Group Educational Event 28 th January 2014 West Suffolk Hospital Education.
Managing T2DM during Ramadan Dr. Asrar Said Hashem Specialist in Internal Medicine (Al-Amiri Hospital) Fellow of KIMS Endocrine, Diabetes and Metabolism.
Monitoring diabetes Diabetes Outreach (March 2011)
No difference between different types of 3 rd line agent Meta analysis. 19 Articles, c 5k patients Cross et al Ann Int Med 2011.
 GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose  Type 2 diabetics little incretin effect  Reduced GLP-1 secretion.
The New HbA1c HbA1c – DCCT (%) HbA1c – IFFC (mmol/mol)
Diabetes and dementia Jackie watts Clinical Advisor Diabetes UK.
BHS Guidelines for the management of hypertension BHS IV, 2004 and Update of the NICE Hypertension Guideline, 2006 Guidelines for management of hypertension:
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Dr Kiran Sodha Patient Participation Group October 2014
Barriers to Diabetes Control Mark E. Molitch, MD.
LONG TERM BENEFITS OF ORAL AGENTS
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
Novel Antidiabetics: Should they be used at all - and in whom?
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
DIABETES MELLLITUS Strategies for Achieving Control in an Office Setting.
Drugs used in Diabetes Dr Sally Hudson. BIGUANIDES reduce output of glucose from the liver and enhances uptake and use of glucose by muscle cells ExampleADVANTAGESDISADVANTAGESCOSTCaution.
Insulin in Primary Care Dr Saqib Mahmud, MRCP(UK), MRCGP.
EXERCISE PREVENTION Helmich, S.P. et al. New England J Medicine 325: , 199 Incidence Rates of type 2 (/ 10,000 man-years.
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
Preferred treatment options for patients with Diabetes Dr Jon Tuppen GPwSI Beechwood Surgery Brentwood.
Journal Club 2009 年 1 月 29 日(木) 8 : 20 ~ 8 : 50 B 棟 8 階カンファレンスルーム 薬剤部 TTSP 石井 英俊.
After eating, most food is turned into glucose, the body’s main source of energy. What Happens When We Eat? American Diabetes Association.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Insulin Conundrums Veronica Green *p < **p = Epidemiological extrapolation showing benefit of a 1% reduction in mean HbA 1c with a mean.
Diabetes Therapy in the Elderly Epidemiology –>20% of patients over 65 have DM2 –10% of diabetes cases are diagnosed after the age of 65 Research and Evidence.
Salt, Heart Disease, and Stroke Norm Campbell. 1) The role of increased blood pressure as a determinant of adverse outcomes 2) The health risks of high.
DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
A Diabetes Outcome Progression Trial
Individualization Strategies for Older Patients with Diabetes Elbert S. Huang, MD MPH FACP University of Chicago.
January 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
Type 2 diabetes treatment: Old and New Emily Szmuilowicz, MD, MS Assistant Professor of Medicine Division of Endocrinology Northwestern University.
Polypill x Aspirin Project Groups 3 and 4
An initiative of South Asian Federation of Endocrine Societies (SAFES)
Dixie L. Thompson chapter 20 Exercise and Diabetes.
Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.
MODERN ART in TYPE 2 DIABETES Ken McHardy CRAIGMONIE HOTEL, INVERNESS 11 TH Nov 2011.
1 ‘Medicines used in the management of Type 2 Diabetes’ Dr Susan McGeoch, Specialist Registrar in Diabetes Sandra Wilson, Diabetes Specialist Nurse.
Insulin Optimisation Workshop Theingi Aung & Claire Rowell.
Journal Club 9/15/11 Sanaz Sakiani, MD 1 st Year Endocrine Fellow Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics.
Who is considered elderly? “Young old” years “Old, old” >75 years.
Abbey Medical Practice Personalised Diabetic Care Wednesday 10 th September 2014.
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
Managing Patients with Diabetes on the Haemodialysis Unit Jo Reed Diabetes Specialist Nurse (Renal) November 2015.
Primary Care Prescribing for Type 2 Diabetes Dr. David Jenkins Worcestershire Royal Hospital.
Dr Sheetal Saggar GP.  Bolton Diabetic Centre ◦ Consultants (4) ◦ Specialist Nurses (8) ◦ Podiatry ◦ Dietetics  General Practice ◦ Structure of diabetic.
GLP-1 agonists Ian Gallen Consultant Community Diabetologist
Dr Mohammed Babsail, Dr Bhavin Bakrania
Drugs for Type 2 Diabetes – where next after metformin ?
Dr John Cox Diabetes in Primary Care Conference Cork
Diabetes Learning Event 7th October 2016
Management of Diabetes in the Older Person
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
HbA1c before Ramadan (%)
Recurrent falls in an older woman with diabetes
Therapy of Type 2 Diabetes Mellitus: UPDATE
Diabetes Health Status Report
Ageing with ideal cardiovascular risk factors
Management of Diabetes in the Older Person
Macrovascular Complications Microvascular Complications
Monitoring in Type 2 Diabetes
Type 2 diabetes.
Diabetes Specialist Nurses
Carbohydrate absorption inhibitors α-glucosidose inhibitors
Priorities for Type 2 Diabetes
Presentation transcript:

Diabetes in the older person Terry Aspray Tuesday pm

Diabetes in the older person Diabetes: A future epidemic? New drugs and old people –Old drugs and old people… Can we prevent complications?

A Future Epidemic? Old Age Older population in UK growing Demographics: Projections year –Aged 65+ to rise by 80% –Aged 85+ to rise by 255% Source: Joseph Rowntree foundation Population millions Year

A Future Epidemic? Diabetes In the UK Of people with diabetes –50% aged 65+ –25% aged 75+ Source: Diabetes UK 2004

A Future Epidemic? Diabetes & Death –Community study Population aged 75+ –Diabetic subjects Mortality x4.5 Melton Mowbray Survival- Aged 75+ Yrs Croxson et al Diab Med Survival (%)

A Future Epidemic? Frailty & Care Homes Frail population in UK growing Care homes –450,000 residents Cost £13 billion (2000) –1,130,000 residents Cost £55 billion (2051) Cost £ billions Residents thousands Source: Joseph Rowntree foundation

A Future Epidemic? Diabetes & Care Homes 1630 Residents –1275 had blood tests Diabetes in at least 19.9% –105 new cases –186 already diagnosed EMI Care –Undiagnosed Diabetes common % *(p<0.001) Aspray et al (2006) Diabetes Care Aspray et al (2006) Public Health

A Future Epidemic? ↑Diabetes-all ages Especially in the old ↑Co-morbidities –Age –Diabetes Frailty with diabetes –e.g. Nursing homes

A Future Epidemic? Watch out for Diabetes in 2050… ↑Diabetes-all ages Especially in the old ↑Co-morbidities –Age –Diabetes Frailty with diabetes –e.g. Nursing homes

Case Based Discussion 1. Age 89 F. in a NH –Gliclazide 120mg –Metformin 1.5g –Pioglitazone 30mg –BP 152/72 –HbA1c 5.3% –Urea 7.5; creat 156 –TC 5.5 –Hb10g/dl Questions –Any concerns? –Would you change the treatments?

Case Based Discussion 1. Age 89 F. In a NH Weight 49 kg –Gliclazide 120mg –Metformin 1.5g –Pioglitazone 30mg –Bp 152/72 –HbA1c 5.3% –Urea 7.5; creat 156 –TC 5.5 –Hb 9.8g/dl Concerns –Low HbA1c Any hypos? –Mild anaemia Interpreting HbA1c Glitazone –Renal impairment Metformin Changes –Stop metformin? –Stop Pioglitazone? –Cut gliclazide dose?

Can We Prevent Complications? UKQOF Glucose Points Record of HbA1c in last 15months 3 HbA1c is 7.4 or less in the past 15 months 16 HbA1c is 10 or less in the past 15 months 11 BP HbA1c is 10 or less in the past 15 months 3 BP 145/85 or less in the past 15 months 17 Lipids Record of Cholesterol in last 15months 3 Cholesterol <5mmol in the past 15 months 6

Can We Prevent Complications? QOF & Glucose Not just about bringing down glucose… –No lower limit in QOF for HbA1c Safety first? –Avoiding Osmotic symptoms and Hypos Ensure regular and consistent meals. Consider withdrawal of treatment! Target HbA1c: ? ↑ 1% at %

Hypoglycaemia & Elderly Unawareness in old –↓counter-regulatory response –Take longer to recover. Misdiagnosis: –CVA, TIA –Fit –Confusion ?cause. Therefore:-. –Careful prescribing. –Ensure regular and consistent meals. –Consider withdrawal of treatment!

Benefits of Glucose Control: 2008 trials Intensive glucose control x3 –Target HbA1c % Little CVS benefit? –Already diagnosed DM –Over age 60 –Up to 6 years’ f.u. ↑Risk severe hypos ↑Risk Death (ACCORD) – Thanks to Gillian Hawthorne – BGS Spring Meeting 2009 intervention

Benefits of Glucose Control: 2008 trials Legacy Studies x2 Long Term benefit –New cases T2DM –Urine micro albumin Despite moderate control in long term –HbA1c: 8+% at 10+yrs Intensive glucose control x3 –Target HbA1c % Little CVS benefit? –Already diagnosed DM –Over age 60 –Up to 6 years’ f.u. ↑Risk severe hypos ↑Risk Death (ACCORD) intervention

ADOPT (4351 subjects) *Also Pioglitazone (Takeda) Rosiglitazone █ –Metformin █ –Sulphonylurea █ Hand, humerus, foot –NOT hip or spine Other risks –Cardiovascular (Rosi) –Fluid retention/heart failure –Anaemia Thiazolidinediones & Old People women

Case based discussion 2. 79yrs T2DM 15 yrs –Retinopathy –Neuropathy –BP 188/90 –Glargine/metformin –Bendrofluazide –Lisinoprol –Amlodipine –Atenolol –Why is her BP poorly controlled? –What side effects do you think she suffers from? –What is the target BP?

Case based discussion 2. 79yrs T2DM 15 yrs –Retinopathy –Neuropathy –BP 188/90 –Glargine/metformin –Bendrofluazide –Lisinoprol –Amlodipine –Atenolol –BP Drug adherence –Side effects Diuretic Ca antagonist Combinations… –Target BP Evidence supports Rx at all ages but…

Can We Prevent Complications? BP BHS for Diabetes –start at >140/90 target <130/80… Achievable? HOT 140/81 UKPDS. 144/82 PROGRESS: Post stroke- 138/82- half normotensive HYVET: target <150/80- achieved in 48% Side effects of treatment. –e.g. Orthostatic Hypotension…falls!

Case Based Discussion year old with T2DM for 30 yrs Living with daughter Needs help feeding Incontinent No longer takes tablets as was getting hypos Cholesterol 5.6mmol How should you manage her? Any risks to treatment?

Case Based Discussion year old with T2DM for 30 yrs Living with daughter Requires help with feeding Incontinent No longer takes tablets as was getting hypos Cholesterol 5.6mmol Statin? Risks & benefits of treatment?

Can We Prevent Complications? Lipids Should we give statin? –CVS events ↓by 7-10% at 7 years in the old Dementia: no benefit –(Cochrane 2009) HPS –5% reduction in 5yrs (2P< ) Rate ratio & 95% CI STATIN betterPLACEBO better 24% SE 3 reduction <65 >65 DM No DM DM No DM

Can We Prevent Complications? Lipids Statin safety –1.5x MSK symptoms Mosshammer D 2009 –Only 10% monitor LFTs correctly Leaver 2009 –High dose Atorva is safe up to age 78 Koren MJ 2009 Dementia: no benefit –(Cochrane 2009)

Case Based Discussion 4. Age 72 F. Diabetes for 7 years Gaining weight… –Gliclazide 320mg –Metformin 1.5g –Pioglitazone 45mg –BP 152/72 –HbA1c 9.5% –Urea 4.5; creat 111 Questions –How about insulin? –What if she refuses?

Case Based Discussion 4. Age 71 F. Diabetes for 7 years –Gliclazide 320mg –Metformin 1.5g –Pioglitazone 45mg –BP 152/72 –HbA1c 9.5% –Urea 4.5; creat 111 Insulin –Once daily –Twice daily –Four times daily –With or without OHA Newer Drugs…?

New Drugs: Incretins Insulin release –Response to glucose Orally > I.V. Incretins –Secreted from small bowel –Stimulate beta cells to produce more insulin. Incretin effect

New Drugs: Incretins Incretins: new class of drugs: –GLP-1: exenatide Metabolised by DPP4 –DPP4- inhibitors Oral Gliptins Range of effects –↑Glucose dependent insulin secretion –↓glucagon secretion –Slow gastric emptying –↓ Food intake –↑ Β-cell mass in rats –↑ Insulin sensitivity –↑ Glucose disposal

Incretins in older people Exenatide NICE 3 rd line –Injection –HbA1c ↓1% –Weight ↓ kg Insulin ↑weight! Gliptins NICE 2 nd line –Tablet –HbA1c ↓1% –Weight ↓ kg Incretins for older patients –Theoretically: ↓ β cell mass= less effect –Not licensed monotherapy Exenatide –Benefit into 7 th decade Gliptins –Safe and well tolerated –Efficacy maintained: Glycaemia and Weight

Case Based Discussion 4. Age 66 M. Diabetes for 21 years Poor control for 5 years –BD mix insulin 40/30 –Metformin 1.5g –Very irritable –Poor concentration –Nostalgic for the old days –Diabetes advice going nowhere… Could there be an underlying cause? What do you do?

Case Based Discussion 4. Age 66 M. Diabetes for 21 years Poor control for 5 years –BD mix insulin 40/30 –Metformin 1.5g –Very irritable –Poor concentration –Nostalgic for the old days –Diabetes advice going nowhere… Could there be an underlying cause? Hypoglycaemia??? BM 9.2; then what?

Complications: Dementia Epidemiological Evidence Risk with diabetes… –Alzheimer’s Dementia x2-4 –Vascular Dementia x3 –Diabetes for >15 yrs= x3 Gregg (2000) Arch Int Med 160: Katzmann (1989) Ann Neurol 25: Leibson (1997) Am J Epidemiology 145: Yoshitake (1995) Neurology 45:

Can We Prevent Complications? Dementia Evaluation –Index of suspicion –Is it hypoglycaemia? –MTS (10 item) –MMSE (30 item) –Clock drawing test Draw a clock Put in the numbers Set hands at 10-to-3

Can We Prevent Complications? Dementia HypOglycaemia associate with dementia Kaiser Permanente – –16,667 patients –Mean Age 65yrs Hypo 8.8% Dementia 11% Hypo & Dementia 17% –Link has dose response Age Adjusted Incidence of dementia /10,000 person yrs Whitmer et al. JAMA. 2009;301(15):

Can We Prevent Complications? Dementia HypERglycaemia ↑ HbA1c & ↓ cognition –Digital skills substitution test (DSST) Visuo-motor speed & learning –MMSE Global screening test –Memory score (Rey) Memorise/retrieve words –Stroop Executive skill: response time ACCORD-MIND Diabetes Care 2009… baseline data *P< **P< ** * *

Case Based Discussion 4. Age 66 M. Diabetes for 21 years Poor control for 5 years –BD mix insulin 40/30 –Metformin 1.5g –Very irritable –Poor concentration –Nostalgic for the old days –Diabetes advice going nowhere… Could there be an underlying cause? Needs Dementia work up Consider depression Consider psychological impairment…

Conclusion: Diabetes in older people We have an epidemic –Old People & Diabetes Drugs –Old drugs Benefits- Legacy Risks of tight control –New drugs Glita-bones: Concerns Incretins… Just as effective in the old? Complications –Risks of treatment Orthostatic Hypotension Hypoglycaemia awareness –Dementia Lack of clinician awareness Dysglycaemia causal? Benefits from statins

Conclusion: Diabetes in Older People Complications –Risks of treatment Orthostatic Hypotension Hypoglycaemia awareness –Dementia Lack of clinician awareness Dysglycaemia causal? No benefits from statins